Last reviewed · How we verify
NCT05258877
Pharmacokinetics of Ethionamide and Ethionamide Sulfoxide in Patients Established on Treatment for Tuberculosis.
trial testing Plasma samples in Tuberculosis, Pulmonary in 30 participants. Completed in 30 September 2023.
28 September 2023
Quick facts
| Lead sponsor | BioVersys AG |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 10 June 2022 |
| Primary completion | 28 September 2023 |
| Estimated completion | 30 September 2023 |
| Sites | 1 location across South Africa |
Drugs / interventions tested
- Plasma samples
Conditions studied
- Tuberculosis, Pulmonary — all drugs for Tuberculosis, Pulmonary →
Sponsor
BioVersys AG — full company profile →
Who can join
Adults 18 to 65, any sex, with Tuberculosis, Pulmonary. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine the pharmacokinetics of ethionamide (Eto) and ethionamide-sulfoxide (Eto-SO) in participants with tuberculosis (TB) when Eto is dosed under programmatic conditions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05258877
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tuberculosis, Pulmonary
Currently open trials in the same condition.
- NCT07077213 — 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients · recruiting
- NCT07271225 — Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting · NA · recruiting
- NCT06845618 — Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment · recruiting
- NCT06253715 — Shortened Regimen for Drug-susceptible TB in Children · Phase 3 · recruiting
- NCT06057519 — Pragmatic Optimized Rifampicin Trial · Phase 3 · recruiting
Other BioVersys AG trials
Trials by the same sponsor.
- NCT07350174 — Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis · Phase 2 · not yet recruiting
- NCT05684705 — Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100 · Phase 1 · completed
- NCT05685615 — PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB · Phase 2 · completed
- NCT05684718 — To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100 · Phase 1 · completed
- NCT05537142 — A Study to Assess the Phamacokinetics of BV100 in Participants with Varying Degrees of Hepatic Impairment · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05258877 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BioVersys AG
- Last refreshed: 21 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05258877.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing